Crescent Biopharma, INC. (CBIO) SEC Filings — 2025
13 SEC filings for Crescent Biopharma, INC. (CBIO) in 2025.
Filings
- Crescent Biopharma, INC. 8-K Filing — 8-K · Dec 4, 2025
- Crescent Biopharma's Cash Surges Post-Financing Amidst Deepening Losses — 10-Q · Nov 6, 2025
- Crescent Biopharma Reports Zero Revenue, $20.1M Net Loss Amid Pipeline Development — 10-Q · Jul 31, 2025
- GlycoMimetics Reports Material Definitive Agreement & Asset Changes — 8-K · Jun 18, 2025
- GlycoMimetics Files 8-K: Shareholder Vote, Reg FD, Other Events — 8-K · Jun 6, 2025
- GlycoMimetics Files 8-K Report — 8-K · May 30, 2025
- GlycoMimetics Q1 2025 10-Q Filed — 10-Q · May 14, 2025
- GlycoMimetics Enters Material Definitive Agreement — 8-K · Apr 29, 2025
- GlycoMimetics Reports Agreement Termination & Director Changes — 8-K · Feb 25, 2025
- GlycoMimetics Enters Material Definitive Agreement — 8-K · Feb 14, 2025
- GlycoMimetics Files 2024 10-K, Reports $64.4M Cash — 10-K · Feb 13, 2025
- GlycoMimetics Announces Executive and Director Changes — 8-K · Jan 31, 2025
- Glycomimetics INC 8-K Filing — 8-K · Jan 13, 2025